INmune Bio, Inc. (INMB) vs Lite Strategy, Inc. (LITS)
A side-by-side comparison of INmune Bio, Inc. and Lite Strategy, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INMB
INmune Bio, Inc.
$1.93HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT
LITS
Lite Strategy, Inc.
$1.42HealthcareDelayed quote: Oct 6, 2026, 11:29 AM EDT
Total return — INMB vs LITS
growth of $100 · dividends reinvested · last 1yINMB -1.5% (-1.5%/yr)LITS -69.1% (-69.1%/yr)INMB compounded faster over this window
INMB LITS
INMB vs LITS: by the numbers
- •INMB is the larger company ($51M vs $48M market cap).
- •Both run net losses; LITS's is the smaller (0.00% vs -91866.00% net margin).
Metrics side by side
Valuation
| Metric | INMB | LITS |
|---|---|---|
| P/B ratio | 2.51 | 1.16 |
Profitability
| Metric | INMB | LITS |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -61738.00% | 0.00% |
| Net margin | -91866.00% | 0.00% |
| ROE | -90.44% | -170.94% |
| ROIC | -96.37% | -30.75% |
Growth (annualized)
| Metric | INMB | LITS |
|---|---|---|
| Total return CAGR (5Y) | -36.88% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.